•  
     
    Strategic Planning
    Strategic Planning

    Be a credible threat. As you seek funding, we create product development plans that align clinical and regulatory milestones with costs.

    Development Strategy Used for Fundraising

    Small virtual biotech start-up with stem-cell therapy treatment for HIV. Strong scientific expertise but limited experience in moving research phase work into early clinical (pre-IND) development. No experience in regulatory affairs to understand the dynamic nature of regenerative medicine interactions with FDA.
  •  
     
    Due Diligence
    Due Diligence

    Know what you’re up against. We inform decision making on product acquisition strategies by identifying both regulatory and operational risks.

    Indication Selection

    A Life sciences venture capital firm come to Halloran looking for help prioritizing potential indications for their lead oncology compound.
  •  
     
    Road Mapping
    Road Mapping

    What is possible, and what is probable. We bring together KOL opinions, market assessments, and reality, so you can make the business decisions.

    Starting up a Life Science Division

    A mature, global animal health company wanted to expand into human healthcare.  The company was unsure whether their lead product was ready to advance to IND-enabling activities.  The company also lacked expertise in human clinical product development.

Meet the Plan team leads

Greg Dombal
Chief Operating Officer
Michelle Rose, PhD
Principal Consultant
Iva Toudjarska, MBA, PhD
Principal Consultant
Michael Wienholt, RAC
Principal Consultant